Looking at this filing, I need to identify the key facts. This is a Form 10-Q for Certara, Inc. (NASDAQ:CERT) for the quarterly period ended September 30, 2026, filed November 5, 2026. The filing text is primarily cover page and forward-looking statements boilerplate. Let me check the substantive disclosure content against the 150-word gate. Substantive content includes: share count (152,543,402 shares as of November 1, 2026), the divestiture of regulatory medical writing business mentioned in risk factors, the company's business description references (biosimulation, model-informed biopharmaceutical discovery, software licenses), and various risk factor disclosures. This exceeds 150 words of substantive content, so I proceed.

Certara, Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the fiscal quarter ended September 30, 2026, disclosing share count, business risks, and a completed divestiture of its regulatory medical writing business.

Key Highlights

  • Share count: As of November 1, 2026, Certara had 152,543,402 shares of common stock, par value $0.01 per share, outstanding.
  • Filer classification: Certara is classified as a large accelerated filer, according to the filing.
  • Divestiture disclosed: The company cited its ability to realize expected benefits from the divestiture of its regulatory medical writing business as a forward-looking risk factor.
  • Exchange listing: Common stock trades on The Nasdaq Stock Market LLC under the symbol CERT (NASDAQ:CERT).
  • Incorporation: Certara is incorporated in Delaware, with principal executive offices located at 4 Radnor Corporate Center, Suite 350, Radnor, Pennsylvania 19087.
  • Commission File Number: 001-39799, as stated on the cover page of the quarterly report.

Certara's September 2026 Quarterly Filing: Divestiture, Share Count, and Risk Disclosures

Certara, Inc. (NASDAQ:CERT), a biosimulation and model-informed drug development company headquartered in Radnor, Pennsylvania, submitted its Form 10-Q for the quarterly period ended September 30, 2026. The filing confirms that as of November 1, 2026, the company had 152,543,402 shares of common stock outstanding at a par value of $0.01 per share. Certara is classified as a large accelerated filer and is not a shell company, according to the cover page disclosures.

The filing references the divestiture of Certara's regulatory medical writing business as a notable development, listing "our ability to realize the expected benefits of the divestiture of our regulatory medical writing business" among the forward-looking risk factors. The company provides biosimulation software and services to biopharmaceutical customers, with revenue dependent on software license renewals, customer R&D spending levels, and adoption of model-informed drug development approaches, the filing stated.

Among the risk factors disclosed, the company noted potential headwinds including consolidation within the biopharmaceutical industry, operational disruptions at the FDA and other government agencies, competition in a "competitive and highly fragmented market," and risks associated with artificial intelligence and machine learning in its products and services. The filing also flagged customer concentration risk, noting that "the loss of one or more of our major customers could materially and adversely affect our business, results of operations and/or financial condition." All forward-looking statements in the quarterly report are subject to the company's cautionary language and the safe harbor provisions of Sections 27A and 21E of the applicable securities acts.

What Was Disclosed

Certara, Inc. filed a Form 10-Q for the quarter ended September 30, 2026, reporting 152,543,402 shares outstanding as of November 1, 2026, confirming its large accelerated filer status, referencing the divestiture of its regulatory medical writing business, and outlining a range of forward-looking risk factors specific to its biosimulation and drug development software business.